Challenge Conventional ThinkingView Our Research
What We Do
Prescience Point Capital Management is a research-focused, catalyst-driven investment firm that seeks to earn superior risk-adjusted returns uncorrelated to the broader market. Unlike traditional investment strategies, we are unconstrained and can opportunistically invest globally, across asset classes, industry verticals and capital structures. Whether investing in misunderstood distressed assets, creating value through shareholder activism, or uncovering fraud, we seek to capitalize on opportunities that others miss or fall outside the rigid mandates of most investment firms. Our uniqueness resides in our unconventional thinking, deep research, intellectual curiosity and willingness to go against the prevailing wisdom.
Sign up for report updates
Institutional Investor Magazine sat down with our founder Eiad Asbahi for a wide ranging profile on the firm’s strategy, history and latest short idea (Link…
Prescience Point Capital Management, together with its affiliates (“Prescience Point”), a research-focused, catalyst-driven investment firm, announced today the nomination of four highly qualified director candidates…
December 21, 2021
Groupon Inc. | GRPN
While most think Groupon is dead, it has a valuable secret asset, a surprisingly loyal user base and a revamped core biz poised for increased growth. Shares could quadruple.
November 17, 2021
AerSale Corp. | ASLE – Update
We have updated our report on AerSale Corp. following positive comments from the company's Q3 2021 earnings call, which confirmed and strengthened our initial thesis.
October 27, 2021
AerSale Corp. | ASLE
Prescience Point believes that AerSale Corp, a provider of aftermarket aircraft services and equipment, could more than double over the near-term thanks to several catalysts
December 16, 2020
Mimedx Group Inc. | MDXG – Update
We are raising our price target on MiMedx Group to $31 per share based on extensive new research showing that MiMedx’s Amniofix treatment will be a blockbuster for knee OA
June 17, 2020
Enphase Energy | ENPH – Update 2
Extensive research reveals smoking gun evidence of massive fraud by ENPH; we believe at least $205m of revenue has been fabricated. We are short the stock and expect a delisting.